Ngā hua rapu

Review: Targeting the Hedgehog pathway in cancer mā Sachin Gupta, Naoko Takebe, Patricia LoRusso

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects mā Richard Graham, Cornelis E. C. A. Hop, Marie T. Borin, Bert L. Lum, Dawn Colburn, Ilsung Chang, Young G. Shin, Vikram Malhi, Jennifer A. Low, Mark J. Dresser

Whiwhi kuputuhi katoa

Non-Canonical Hh Signaling in Cancer—Current Understanding and Future Directions mā Dongsheng Gu, Jingwu Xie

Whiwhi kuputuhi katoa

GLI2 is a novel therapeutic target for metastasis of osteosarcoma mā Hiroko Nagao‐Kitamoto, Masahito Nagata, Satoshi Nagano, Sho Kitamoto, Yasuhiro Ishidou, Takuya Yamamoto, Shunsuke Nakamura, Arisa Tsuru, Masahiko Abematsu, Yusuke Fujimoto, Masahiro Yokouchi, Shinichi Kitajima, Takako Yoshioka, Shingo Maeda, Suguru Yonezawa, Setsuro Komiya, Takao Setoguchi

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Midline carcinoma with t(15;19) and BRD4-NUTfusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy mā Jens Engleson, Maria Soller, Ioannis Panagopoulos, Anna Dahlén, Michael Dictor, Mats Jerkeman

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma mā Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard Mackey, B. Lum, Walter C. Darbonne, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma mā Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf, Nicole Basset‐Séguin, Zora Modrušan, Thomas Januario, Vickie Tsui, Alison B. Durham, Andrzej A. Dlugosz, Peter M. Haverty, Richard Bourgon, Jean Y. Tang, Kavita Y. Sarin, Luc Dirix, David C. Fisher, Charles M. Rudin, Howard Sofen, Michael R. Migden, Robert L. Yauch, Frédéric J. de Sauvage

Whiwhi kuputuhi katoa

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma mā Erqi L. Pollom, Timothy T. Bui, Anne Lynn S. Chang, A. Dimitrios Colevas, Wendy Hara

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Definition of Critical Periods for Hedgehog Pathway Antagonist-Induced Holoprosencephaly, Cleft Lip, and Cleft Palate mā Galen W. Heyne, Cal G. Melberg, Padydeh Doroodchi, Kia F. Parins, Henry W. Kietzman, Joshua L. Everson, Lydia J. Ansen-Wilson, Robert J. Lipinski

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Novel Hedgehog pathway targets against basal cell carcinoma mā Jean Y. Tang, Po‐Wah So, E EPSTEINJR

Whiwhi kuputuhi katoa

Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes mā Monica Dentice, Cristina Luongo, Stephen A. Huang, Raffaele Ambrosio, Antonia Elefante, Delphine Mirebeau‐Prunier, Ann Marie Zavacki, Gianfranco Fenzi, Marina Grachtchouk, Mark E. Hutchin, Andrzej A. Dlugosz, Antônio C. Bianco, Caterina Missero, P. Reed Larsen, Domenico Salvatore

Whiwhi kuputuhi katoa

Small‐Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics mā Stefan Peukert, Karen Miller‐Moslin

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma mā Anne Lynn S. Chang, Anthony E. Oro

Whiwhi kuputuhi katoa

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma mā Sabrina Pricl, Barbara Cortelazzi, Valentina Dal Col, Domenico Marson, Erik Laurini, Maurizio Fermeglia, Lisa Licitra, Silvana Pilotti, Paolo Bossi, Federica Perrone

Whiwhi kuputuhi katoa

Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma mā Edward Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Khan, John Blau, Ronald A. Craig, Ulysses J. Balis, Mark M. Zalupski, Diane M. Simeone

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds mā Hyekyung Yang, Wei‐na Cong, Jeong Seon Yoon, Josephine M. Egan

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma mā Howard Sofen, Kenneth G. Gross, Leonard H. Goldberg, Harry H. Sharata, Tiffani K. Hamilton, Barbara M. Egbert, Benjamin Lyons, Jeannie Hou, Ivor Caro

Whiwhi kuputuhi katoa

Vismodegib for Periocular and Orbital Basal Cell Carcinoma mā Harmeet Gill, Eve E. Moscato, Anne Lynn S. Chang, Seaver L. Soon, Rona Z. Silkiss

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

The dawn of hedgehog inhibitors: Vismodegib mā Sandhiya Selvarajan, George Melvin, Srinivasamurthy Suresh Kumar, Steven Aibor Dkhar

Whiwhi kuputuhi katoa

Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome mā Jean Y. Tang, Julian Mackay‐Wiggan, Michelle Aszterbaum, Robert L. Yauch, Joselyn Lindgren, Kris S. Chang, Carol Coppola, Anita M. Chanana, Jackleen Marji, David R. Bickers, Ervin H. Epstein

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa